Table of Content

1. Key Insights

2. Executive Summary of SCLC

3. SWOT Analysis for SCLC

4. SCLC: Market Overview at a Glance
4.1. Total Market Share (%) Distribution of SCLC in 2017
4.2. Total Market Share (%) Distribution of SCLC in 2030

5. Small Cell Lung Cancer (SCLC): Disease Background and Overview
5.1. Introduction
5.1.1. Signs and Symptoms of Lung Cancer
5.1.2. Risk Factors of SCLC
5.1.3. Causes of SCLC
5.1.4. Disease Biology: SCLC
5.2. Diagnosis of Small-cell Lung Cancer (SCLC)
5.2.1. Imaging tests
5.2.2. Staging in SCLC

6. Epidemiology and Patient Population
6.1. Epidemiology Key Findings
6.2. Assumptions and Rationale: 7MM
6.3. Total Incidence of Lung Cancer in the 7MM
6.4. Total Incidence cases of SCLC in the 7MM

7. United States
7.1. Total Incidence cases of SCLC in the United States
7.2. Gender-specific Incidence of SCLC in the United States
7.3. Age-specific Incidence of SCLC in the United States
7.4. Stage-Specific Incidence of SCLC in the United States
7.5. Line-wise Treatment of Extensive-Stage SCLC in the United States

8. EU-5 Country-wise Epidemiology
8.1. Germany
8.1.1. Total Incidence cases of SCLC in Germany
8.1.2. Gender-specific Incidence of SCLC in Germany
8.1.3. Age-specific Incidence of SCLC in Germany
8.1.4. Stage-Specific Incidence of SCLC in Germany
8.1.5. Line-wise Treatment of Extensive-Stage SCLC in Germany
8.2. France
8.2.1. Total Incidence cases of SCLC in France
8.2.2. Gender-specific Incidence of SCLC in France
8.2.3. Age-specific Incidence of SCLC in France
8.2.4. Stage-Specific Incidence of SCLC in France
8.2.5. Line-wise Treatment of Extensive-Stage SCLC in France
8.3. Italy
8.3.1. Total Incidence cases of SCLC in Italy
8.3.2. Gender-specific Incidence of SCLC in Italy
8.3.3. Age-specific Incidence of SCLC in Italy
8.3.4. Stage-Specific Incidence of SCLC in Italy
8.3.5. Line-wise Treatment of Extensive-Stage SCLC in Italy
8.4. Spain
8.4.1. Total Incidence cases of SCLC in Spain
8.4.2. Gender-specific Incidence of SCLC in Spain
8.4.3. Age-specific Incidence of SCLC in Spain
8.4.4. Stage-Specific Incidence of SCLC in Spain
8.4.5. Line-wise Treatment of Extensive-Stage SCLC in Spain
8.5. United Kingdom
8.5.1. Total Incidence cases of SCLC in the United Kingdom
8.5.2. Gender-specific Incidence of SCLC in the United Kingdom
8.5.3. Age-specific Incidence of SCLC in the United Kingdom
8.5.4. Stage-Specific Incidence of SCLC in the United Kingdom
8.5.5. Line-wise Treatment of Extensive-Stage SCLC in the United Kingdom

9. Japan
9.1. Total Incidence cases of SCLC in Japan
9.2. Gender-specific Incidence of SCLC in Japan
9.3. Age-specific Incidence of SCLC in Japan
9.4. Stage-Specific Incidence of SCLC in Japan
9.5. Line-wise Treatment of Extensive-Stage SCLC in Japan

10. Current Treatment Practices for Small-cell Lung Cancer (SCLC)
10.1. Management Algorithm of SCLC
10.2. SCLC Treatment Paradigm
10.3. Radiation Therapy
10.4. Surgery
10.5. Metastatic Lung Cancer
10.6. Remission and the Chance of Recurrence
10.7. Guidelines for SCLC
10.7.1. Treatment Differences across 7MM
10.7.2. ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up
10.7.3. The American College of Chest Physicians (ACCP) Clinical Practice Guidelines: SCLC

11. Patient Journey

12. Unmet Needs

13. Key Endpoints in SCLC Clinical Trials

14. Marketed Products
14.1. Opdivo (Nivolumab): Bristol-Myers Squibb/ Ono Pharmaceutical
14.1.1. Product Description
14.1.2. Regulatory Milestones
14.1.3. Other Developmental Activities
14.1.4. Pivotal Clinical Trials
14.1.5. Ongoing Clinical Trials Information
14.1.6. Safety and Efficacy of Ongoing Trials
14.2. Keytruda (Pembrolizumab): Merck
14.2.1. Product Description
14.2.2. Regulatory Milestones
14.2.3. Other Developmental Activities
14.2.4. Pivotal Clinical Trials
14.2.5. Ongoing Clinical Trials Information
14.2.6. Safety and Efficacy of Ongoing Trials
14.3. Tecentriq (Atezolizumab): Hoffmann-La Roche
14.3.1. Product Description
14.3.2. Regulatory Milestones
14.3.3. Other Developmental Activities
14.3.4. Pivotal Clinical Trials
14.3.5. Ongoing Clinical Trials Information
14.3.6. Safety and Efficacy of Ongoing Clinical Trials

15. Emerging Therapies
15.1. Key Cross
15.2. Imfinzi +/- tremelimumab: AstraZeneca
15.2.1. Product Description
15.2.2. Regulatory Milestones
15.2.3. Other Developmental Activities
15.2.4. Clinical Development
15.2.5. Safety and Efficacy
15.3. Lurbinectedin (PM01183): PharmaMar
15.3.1. Product Description
15.3.2. Other Developmental Activities
15.3.3. Clinical Development
15.3.4. Safety and Efficacy
15.4. RRx-001: EpicentRx
15.4.1. Product Description
15.4.2. Other Developmental Activities
15.4.3. Clinical Development
15.4.4. Safety and Efficacy
15.5. Dinutuximab (Unituxin): United Therapeutics
15.5.1. Product Description
15.5.2. Other Developmental Activities
15.5.3. Clinical Development
15.5.4. Safety and Efficacy
15.6. Irinotecan liposome injection: Ipsen
15.6.1. Product Description
15.6.2. Other Developmental Activities
15.6.3. Clinical Development
15.6.4. Safety and Efficacy
15.7. Trilaciclib (G1T28): G1 Therapeutics
15.7.1. Product Description
15.7.2. Other Developmental Activities
15.7.3. Clinical Development
15.7.4. Safety and Efficacy
15.8. Dendritic Cell-based p53 Vaccine + Nivolumab + Ipilimumab: MultiVir
15.8.1. Product Description
15.8.2. Other Developmental Activities
15.8.3. Clinical Development
15.8.4. Safety and Efficacy
15.9. Guadecitabine + Carboplatin: Otsuka Holdings
15.9.1. Product Description
15.9.2. Other Developmental Activities
15.9.3. Clinical Development
15.10. Iclusig (ponatinib): Takeda
15.10.1. Product Description
15.10.2. Other Developmental Activities
15.10.3. Clinical Development
15.10.4. Safety and Efficacy

16. Conjoint Analysis of Small Cell Lung Cancer (SCLC) Therapies

17. Small Cell Lung Cancer (SCLC): Seven Major Market Analysis
17.1. Key Findings
17.2. Market Outlook: 7MM
17.3. Total Market Size of SCLC in the 7MM
17.4. Market Size of SCLC by Therapeutic Class in the 7MM

18. United States Market Size
18.1. Total Market size of SCLC in the United States

19. EU-5 Market Size
19.1. Germany Market Size
19.1.1. Total Market size of SCLC in Germany
19.2. France Market Size
19.2.1. Total Market size of SCLC in France
19.3. Italy Market Size
19.3.1. Total Market size of SCLC in Italy
19.4. Spain Market Size
19.4.1. Total Market size of SCLC in Spain
19.5. United Kingdom Market Size
19.5.1. Total Market size of SCLC in the United Kingdom
20. Japan Market Size
20.1. Total Market size of SCLC in Japan
21. Market Access and Reimbursement Scenario of SCLC Therapies
22. Market Drivers
23. Market Barriers
24. Appendix
24.1. Bibliography
24.2. Report Methodology
25. Disclaimer
26. DelveInsight Capabilities
27. About DelveInsight



List of Figures


Figure 1 SCLC SWOT Analysis
Figure 2 Some of the Areas for Current Therapeutic Interest in SCLC
Figure 3 Sign and Symptoms of SCLC
Figure 4 Risks Factors of SCLC
Figure 5 Imaging Tests for SCLC
Figure 6 Stages of SCLC
Figure 7 Global Heat Map of Lung Cancer
Figure 8 Total Incidence of Lung Cancer in the 7MM (2017–2030)
Figure 9 Total Incidence cases of SCLC in the 7MM (2017–2030)
Figure 10 Total Incidence cases of SCLC in the United States (2017–2030)
Figure 11 Gender-specific Incidence of SCLC in the United States (2017–2030)
Figure 12 Age-specific Incidence of SCLC in the United States (2017–2030)
Figure 13 Stage-Specific Incidence of SCLC in the United States (2017–2030)
Figure 14 Line-wise Treatment of Extensive-Stage SCLC in the United States (2017–2030)
Figure 15 Total Incidence cases of SCLC in Germany (2017–2030)
Figure 16 Gender-specific Incidence of SCLC in Germany (2017–2030)
Figure 17 Age-specific Incidence of SCLC in Germany (2017–2030)
Figure 18 Stage-Specific Incidence of SCLC in Germany (2017–2030)
Figure 19 Line-wise Treatment of Extensive-Stage SCLC in Germany (2017–2030)
Figure 20 Total Incidence cases of SCLC in France (2017–2030)
Figure 21 Gender-specific Incidence of SCLC in France (2017–2030)
Figure 22 Age-specific Incidence of SCLC in France (2017–2030)
Figure 23 Stage-Specific Incidence of SCLC in France (2017–2030)
Figure 24 Line-wise Treatment of Extensive-Stage SCLC in France (2017–2030)
Figure 25 Total Incidence cases of SCLC in Italy (2017–2030)
Figure 26 Gender-specific Incidence of SCLC in Italy (2017–2030)
Figure 27 Age-specific Incidence of SCLC in Italy (2017–2030)
Figure 28 Stage-Specific Incidence of SCLC in Italy (2017–2030)
Figure 29 Line-wise Treatment of Extensive-Stage SCLC in Italy (2017–2030)
Figure 30 Total Incidence cases of SCLC in Spain (2017–2030)
Figure 31 Gender-specific Incidence of SCLC in Spain (2017–2030)
Figure 32 Age-specific Incidence of SCLC in Spain (2017–2030)
Figure 33 Stage-Specific Incidence of SCLC in Spain (2017–2030)
Figure 34 Line-wise Treatment of Extensive-Stage SCLC in Spain (2017–2030)
Figure 35 Total Incidence cases of SCLC in the United Kingdom (2017–2030)
Figure 36 Gender-specific Incidence of SCLC in the United Kingdom (2017–2030)
Figure 37 Age-specific Incidence of SCLC in the United Kingdom (2017–2030)
Figure 38 Stage-Specific Incidence of SCLC in the United Kingdom (2017–2030)
Figure 39 Line-wise Treatment of Extensive-Stage SCLC in the United Kingdom (2017–2030)
Figure 40 Total Incidence cases of SCLC in Japan (2017–2030)
Figure 41 Gender-specific Incidence of SCLC in Japan (2017–2030)
Figure 42 Age-specific Incidence of SCLC in Japan (2017–2030)
Figure 43 Stage-Specific Incidence of SCLC in Japan (2017–2030)
Figure 44 Line-wise Treatment of Extensive-Stage SCLC in Japan (2017–2030)
Figure 45 Initial Management Algorithm of SCLC
Figure 46 Management of Relapsed/Refractory SCLC
Figure 47 SCLC Treatment Algorithm by ESMO
Figure 48 Unmet Needs of SCLC
Figure 49 Market Size of SCLC in the 7MM Countries in USD Million (2017–2030)
Figure 50 Market Size of SCLC by Line of therapies in the 7MM, in USD Million (2017–2030)
Figure 51 Market Size of SCLC in the US, USD Millions (2017–2030)
Figure 52 Market Size of SCLC in Germany, USD Millions (2017–2030)
Figure 53 Market Size of SCLC in France, USD Millions (2017–2030)
Figure 54 Market Size of SCLC in Italy, USD Millions (2017–2030)
Figure 55 Market Size of SCLC in Spain, USD Millions (2017–2030)
Figure 56 Market Size of SCLC in the United Kingdom USD Millions (2017–2030)
Figure 57 Market Size of SCLC in Japan, USD Millions (2017–2030)
Figure 58 Market Drivers of SCLC
Figure 59 Market Barriers of SCLC

 

List of Tables


Table 1 Summary of Small-cell Lung Cancer (SCLC)Market, Epidemiology, and Key Events (2017–2030)
Table 2 Molecular Aberrations of SCLC
Table 3 TNM Staging of SCLC
Table 4 Major Sources Used
Table 5 Total Incidence of Lung Cancer in the 7MM (2017–2030)
Table 6 Total Incidence cases of SCLC in the 7MM (2017–2030)
Table 7 Total Incidence cases of SCLC in the United States (2017–2030)
Table 8 Gender-specific Incidence of SCLC in the United States (2017–2030)
Table 9 Age-specific Incidence of SCLC in the United States (2017–2030)
Table 10 Stage-Specific Incidence of SCLC in the United States (2017–2030)
Table 11 Line-wise Treatment of Extensive-Stage SCLC in the United States (2017–2030)
Table 12 Total Incidence cases of SCLC in Germany (2017–2030)
Table 13 Gender-specific Incidence of SCLC in Germany (2017–2030)
Table 14 Age-specific Incidence of SCLC in Germany (2017–2030)
Table 15 Stage-Specific Incidence of SCLC in Germany (2017–2030)
Table 16 Line-wise Treatment of Extensive-Stage SCLC in Germany (2017–2030)
Table 17 Total Incidence cases of SCLC in France (2017–2030)
Table 18 Gender-specific Incidence of SCLC in France (2017–2030)
Table 19 Age-specific Incidence of SCLC in France (2017–2030)
Table 20 Stage-Specific Incidence of SCLC in France (2017–2030)
Table 21 Line-wise Treatment of Extensive-Stage SCLC in France (2017–2030)
Table 22 Total Incidence cases of SCLC in Italy (2017–2030)
Table 23 Gender-specific Incidence of SCLC in Italy (2017–2030)
Table 24 Age-specific Incidence of SCLC in Italy (2017–2030)
Table 25 Stage-Specific Incidence of SCLC in Italy (2017–2030)
Table 26 Line-wise Treatment of Extensive-Stage SCLC in Italy (2017–2030)
Table 27 Total Incidence cases of SCLC in Spain (2017–2030)
Table 28 Gender-specific Incidence of SCLC in Spain (2017–2030)
Table 29 Age-specific Incidence of SCLC in Spain (2017–2030)
Table 30 Stage-Specific Incidence of SCLC in Spain (2017–2030)
Table 31 Line-wise Treatment of Extensive-Stage SCLC in Spain (2017–2030)
Table 32 Total Incidence cases of SCLC in the United Kingdom (2017–2030)
Table 33 Gender-specific Incidence of SCLC in the United Kingdom (2017–2030)
Table 34 Age-specific Incidence of SCLC in the United Kingdom (2017–2030)
Table 35 Stage-Specific Incidence of SCLC in the United Kingdom (2017–2030)
Table 36 Line-wise Treatment of Extensive-Stage SCLC in the United Kingdom (2017–2030)
Table 37 Total Incidence cases of SCLC in Japan (2017–2030)
Table 38 Age-specific Incidence of SCLC in Japan (2017–2030)
Table 39 Age-specific Incidence of SCLC in Japan (2017–2030)
Table 40 Stage-Specific Incidence of SCLC in Japan (2017–2030)
Table 41 Line-wise Treatment of Extensive-Stage SCLC in Japan (2017–2030)
Table 42 ASCO Key Recommendations for Treatment of SCLC
Table 43 Opdivo (Nivolumab), Clinical Trial Description
Table 44 Keytruda, Clinical Trial Description 2020
Table 45 Tecentriq, Clinical Trial Description, 2020
Table 46 Emerging Drugs Key-cross Competition
Table 47 Imfinzi +/- tremelimumab, Clinical Trial Description, 2020
Table 48 Lurbinectedin (PM01183), Clinical Trial Description, 2020
Table 49 RRx-001, Clinical Trial Description, 2020
Table 50 Dinutuximab (Unituxin), Clinical Trial Description, 2020
Table 51 Irinotecan liposome injection, Clinical Trial Description, 2020
Table 52 Trilaciclib (G1T28), Clinical Trial Description, 2020
Table 53 Dendritic Cell based p53 Vaccine + Nivolumab + Ipilimumab, Clinical Trial Description, 2020
Table 54 Guadecitabine, Clinical Trial Description, 2020
Table 55 Iclusig (ponatinib), Clinical Trial Description, 2020
Table 56 List of Marketed Products with their respective Therapeutic Classes
Table 57 7MM Market Size of SCLC in USD Million (2017–2030)
Table 58 7MM Market Size of SCLC By Line of Therapy in USD Million (2017–2030)
Table 59 7MM Market Size of SCLC by therapies in USD Million (2017–2030)
Table 60 United States Market Size of SCLC By Line of Therapy in USD Million (2017–2030)
Table 61 United States Market Size of SCLC by Therapies in USD Million (2017–2030)
Table 62 Germany Market Size of SCLC By Line of Therapy in USD Million (2017–2030)
Table 63 Germany Market Size of SCLC by Therapies in USD Million (2017–2030)
Table 64 France Market Size of SCLC By Line of Therapy in USD Million (2017–2030)
Table 65 France Market Size of SCLC by Therapies in USD Million (2017–2030)
Table 66 Italy Market Size of SCLC By Line of Therapy in USD Million (2017–2030)
Table 67 Italy Market Size of SCLC by Therapies in USD Million (2017–2030)
Table 68 Spain Market Size of SCLC By Line of Therapy in USD Million (2017–2030)
Table 69 Spain Market Size of SCLC by Therapies in USD Million (2017–2030)
Table 70 United Kingdom Market Size of SCLC By Line of Therapy in USD Million (2017–2030)
Table 71 United Kingdom Market Size of SCLC by Therapies in USD Million (2017–2030)
Table 72 Japan Market Size of SCLC By Line of Therapy in USD Million (2017–2030)
Table 73 Japan Market Size of SCLC by Therapies in USD Million (2017–2030)